Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Platinum Resistant or Refractory Ovarian Cancer
NCT03924882Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in ovarian cancer, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate up to 3 years. Status: unknown.
02
Drugs
anlotinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03924882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03924882.